MÆDICA - a Journal of Clinical Medicine | Vol. 10, nr. 2, 2015

ISSN 1841-9038  |  e-ISSN 2069-6116
ISSN-L 1841-9038


Plagiatul – in actualitate

Tema plagiatului este tot mai mult discutata in ultima vreme. Aparitia unor programe performante de cautare si identificare a similitudinilor intre texte [...]

Committe on Publication Ethics

A forum for responsible and ethical research publishing – Code of Conduct and Best Practice Guidelines for Journal Editors.

Members Area

PAI-1 Inhibition – Another Therapeutic Option for Cardiovascular Protection



Current research suggest that plasminogen activator inhibitor type 1 (PAI-1) is an important contributor to a number of disease processes. The aim of the current paper is to emphasize the deleterious effects of PAI-1 on cardiovascular diseases development and progression. The plasminogen system is known by its role in hemostasis and thrombosis regulation. Lifestyle changes and pharmacological treatment can regulate PAI-1 levels and functions.
Some pharmacologic agents currently used in the management of atherosclerosis and its complications can counteract the deleterious effects of PAI-1.

Keywords: plasminogen activator inhibitor type-1, cardiovascular protection, PAI-1 antagonists

Full text | PDF